Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Kaletra (lopinavir and ritonavir) Solution for Oral Use


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- June 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

 

Sections Modified Summary of Changes to Contraindications and Warnings

CONTRAINDICATIONS

  • Initial Statement
  • Table 3: Drugs That Are Contraindicated With Kaletra

ADVERSE REACTIONS

  • Pediatric Patients - Clinical Trials Experience

DRUG INTERACTIONS

  • Table 9
    • Benzodiazepines:
      Parenterally
      Administered
      Midazolam

USE IN SPECIFIC POPULATIONS

  • Pediatric Use

PATIENT PACKAGE INSERT

  • What is Kaletra and how does it work?
    • ...Kaletra is for adults and for children age 14 days and older.
  • How should I take Kaletra?
    • Dosing in children greater than 14 days of age...

CONTRAINDICATIONS

Kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir.

Table 3: Drugs That Are Contraindicated With Kaletra

Sedative/Hyponotics:

  • Orally Administered Midazolam (added)
-
-